Active and non-active progression independent of relapse activity within the first 20 years of relapsing multiple sclerosis.

This study evidenced that inflammatory activity increases the risk of PIRA in early RMS, arguing that a significant part of PIRA is accessible to treatment targeting inflammation in these patients.